Clinical and molecular insights into lymphangioleiomyomatosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 22, Issue SUPPL. 1, 2005, Pages

  Steagall, Wendy K ^a   Taveira DaSilva, Angela M ^a   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Angiomyolipoma; Hamartin; Loss of heterozygosity; Lymphangioleiomyomatosis; Meningioma; Metastasis; Pulmonary function test; Tuberin

Indexed keywords

HAMARTIN; PROTEIN 14 3 3;

AUTOSOMAL INHERITANCE; BRAIN METASTASIS; CELL PROLIFERATION; CONFERENCE PAPER; EXERCISE TEST; FLOW RATE; FORCED EXPIRATORY VOLUME; GAS EXCHANGE; GENE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LYMPHANGIOLEIOMYOMATOSIS; MENINGIOMA; PRIORITY JOURNAL; RARE DISEASE; TSC1 GENE; TSC2 GENE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

BIOPSY, NEEDLE; BRONCHOALVEOLAR LAVAGE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MALE; MUTATION; NEOPLASM STAGING; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 31544456387     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (194)

1. Aubry MC, Myers JL, Ryu JH, et al: Pulmonary lymphangioleiomyomatosis in a man. Am J Respir Crit Care Med 2000; 162: 749-52.
2. Lutembacher R: Dysembryomes metatypique des reins: carcinose submiliaire du poumon avec emphysema generalisé et double pneumothorax. Ann Med 1918; 5: 435-50.
3. von Stossel E: Über muskulare Cirrhose der Lunge. Beitr Klin Tuberk 1937; 90: 432-42.
4. Cornog JL, Enterline HT: Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytoma. Cancer 1966; 19: 1909-30.
5. Carrington CB, Cugell DW, Gaensler EA, et al: Lymphangioleiomyomatosis: physiologic pathologic radiologic correlations. Am Rev Respir Dis 1977; 116: 977-95.
6. Taylor JR, Ryu J, Colby TV, Raffin TA: Lymphangioleiomyomatosis: clinical course in 32 patients. N Engl J Med 1990; 323: 1254-60.
7. Kitaichi M, Nishimura K, Harumi I, Izumi T: Pulmonary lymphangiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995; 151: 527-33.
8. Urban TJ, Lazor R, Lacronique J, et al: Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Medicine 1999; 78: 321-37.
9. Chu SC, Horiba K, Usuki J, et al: Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999; 115: 1041-52.
10. Johnson S, Tattersfield AE: Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000; 55: 1052-7.
11. Silverstein EF, Ellis K, Wolff M, et al: Pulmonary lymphangiomyomatosis. Am J Roentgenol 1974; 120: 832-50.
12. Corrin B, Liebow AA, Friedman PJ: Pulmonary lymphangioleiomyomatosis: a review. Am J Pathol 1975; 79: 348-67.
13. Kalassian KG, Doyle R, Kao P, Ruoss S, Raffin TA: Lymphangioleiomyomatosis: new insights. Am J Respir Crit Care Med 1997; 155: 1183-6.
14. Sullivan EJ: Lymphangioleiomyomatosis: a review. Chest 1998; 114: 1689-1703.
15. Johnson S: Lymphangioleiomyomatosis: clinical features, management and basic mechanisms. Thorax 1999; 54: 254-64.
16. Moss J (ed): LAM and Other Diseases Characterized by Smooth Muscle Proliferation. New York, NY: Marcel Dekker Inc. 1999.
17. Ferrans VJ, Yu ZX, Nelson WK, et al: Lymphangioleiomyomatosis (LAM). A review of clinical and morphological features. J Nippon Med Sch 2000; 67: 311-29.
18. Glassberg MK: Lymphangioleiomyomatosis. Clin Chest Med 2004; 25: 573-82.
19. Sullivan EJ, Beck GJ, Peavy HH, Fanburg BL: Lymphangioleiomyomatosis registry. Chest 1999; 115: 301.
20. Costello LC, Hartman TE, Ryu JH: High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000; 75: 591-4.
21. Moss J, Avila N, Barnes PM, et al: Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001; 163: 669-71.
22. Franz DN, Brody A, Meye C, et al: Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001; 164: 661-8.
23. Osborne JP, Fryer A, Webb D: Epidemiology of tuberous sclerosis. Ann NY Acad Sci 1991; 615: 125-7.
24. Cordier JF, Lazor R, the Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires: Perspectives on lymphangioleiomyomatosis in France. In: Moss J, ed: LAM and Other Diseases Characterized by Smooth Muscle Proliferation. New York, NY: Marcel Dekker Inc. 1999: 9-31.
25. Matsui K, Takeda K, Yu Z, et al: Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Path 2001; 25: 479-84.
26. Taveira-DaSilva AM, Hedin CJ, Stylianou MP, et al: Reversible airflow obstruction, proliferation of abnormal smooth muscle cells and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001; 164: 1072-6.
27. Travis WD, Usuki J, Horiba K, Ferrans VJ: Histopathologic studies on lymphangioleiomyomatosis. In: Moss J, ed: LAM and Other Diseases Characterized by Smooth Muscle Cell Proliferation. New York: Marcel Decker Inc. 1999: 171-217.
28. Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J: Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 1999; 21: 327-36.
29. Matsui K, Riemenschneider WK, Hilbert SL, et al: Hyperplasia of Type II pneumocytes in pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000; 124: 1642-8.
30. Usuki J, Horiba K, Chu SC, Moss J, Ferrans VJ: Immunohistochemical analysis of proteins of Bcl-2 family in pulmonary Lymphangioleiomyomatosis. Association of Bcl-2 expression with hormonal receptor status. Arch Pathol Lab Med 1998; 122: 895-902.
31. Berger U, Khaghani A, Pomerance A, Yacoub MH, Coombes RC: Pulmonary lymphangioleiomyomatosis and steroid receptors. Am J Clin Pathol 1990; 93: 609-14.
32. Ohori NP, Yousem SA, Sonmez-Alpan E, et al: Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol 1991; 96: 529-35.
33. Yu J, Astrinidis A, Howard S, Henske EP: Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 2004; 286: L694-L700.
34. Knudson AG: Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996; 122: 135-40.
35. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP: Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998; 62: 810-15.
36. Plank TL, Yeung RS, Henske EP: Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 1998; 58: 4766-70.
37. Van Slegtenhorst M, Nellist M, Nagelkerken B, et al: Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Molec Gen 1998; 7: 1053-7.
38. Nellist M, van Slegtenhorst MA, Goedbloed M, van den Ouweland AMW, Halley DJJ, van der Sluijs P: Characterization of the cytosolic tuberin-hamartin complex. J Biol Chem 1999; 274: 35647-52.
39. Benvenuto G, Li S, Brown SJ, et al: The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000; 19: 6306-16.
40. Van Slegtenhorst M, de Hoogt R, Hermans C, et al: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: 805-8.
41. Krymskaya VP: Tumour suppressors hamartin and tuberin: intracellular signaling. Cell Signal 2003; 15: 729-39.
42. Rosner M, Freilinger A, Hengstschlager M: Proteins interacting with the tuberous sclerosis gene products. Amino Acids 2004; 27: 119-28.
43. Lamb RF, Roy C, Diefenbach TJ, et al: The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2000; 2: 281-7.
44. Fukuhara S, Gutkind JS: A new twist for the tumour suppressor hamartin. Nat Cell Biol 2000; 2: E76-E78.
45. Tsukita S, Yonemura S, Tsukita, S: ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci 1997; 22: 53-8.
46. Haddad LA, Smith N, Bowser M, et al: The TSCI tumor suppressor hamartin interacts with neurofilament-L and possible functions as a novel integrator of the neuronal cytoskeleton. J Biol Chem 2002; 277: 44180-6.
47. The European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75: 1305-15.
48. Li Y, Corradetti MN, Inoki K, Guan K-L: TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 2004; 29: 32-8.
49. Inoki K, Corradetti MN, Guan K-L: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37: 19-24.
50. Soucek T, Pusch O, Wienecke R, DeClue JE, Hengstschlager M: Role of the tuberous sclerosis gene-2 product in cell cycle control. J Biol Chem 1997; 272: 29301-8.
51. Rosner M, Hengstschlager M: Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J Biol Chem 2004; 279: 48707-15.
52. Soucek T, Yeung RS, Hengstschlager M: Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 1998; 95: 15653-8.
53. Soucek T, Rosner M, Miloloza A, et al: Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression. Oncogene 2001; 20: 4904-9.
54. Catania MG, Mishcel PS, Vinters HV: Hamartin and tuberin interaction with the G2/M cyclin-dependent kinase CDK1 and its regulatory cyclins A and B. J Neuropathol Exp Neurol 2001; 60: 711-23.
55. Inoke K, Li Y, Zhu T, Wu J, Guan K-L: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 2002; 4: 648-57.
56. Manning BD, Tee AR, Logson MN, Blenis J, Cantley LC: Identification of tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol Cell 2002; 10: 151-62.
57. Castro AF, Rebhun JF, Clark GJ, Quilliam LA: Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 2003; 278: 32493-6.
58. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J: Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13: 1259-68.
59. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D: Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 2003; 5: 578-81.
60. Gao X, Zhang Y, Arrazola P, et al: TSC tumour suppressor proteins antagonize amino-acid-TOR signaling. Nat Cell Biol 2002; 4: 699-704.
61. Goncharova EA, Goncharov DA, Eszterhas A, et al: Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleimyomatosis (LAM). J Biol Chem 2002; 277: 30958-67.
62. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J: Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 2002; 99: 13571-6.
63. Inoki K, Zhu T, Guan K-L: TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-90.
64. Henry KW, Yuan X, Koszewski NJ, Onda H, Kwiatkowski DJ, Noonan DJ: Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. J Biol Chem 1998; 273: 20535-9.
65. Noonan DJ, Lou D, Griffith N, Vanaman TC: A calmodulin binding site in the tuberous sclerosis 2 gene product is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and lymphangioleiomyomatosis. Arch Biochem Biophys 2002; 398: 132-40.
66. Lou D, Griffith N, Noonan DJ: The tuberous sclerosis 2 gene product can localize to nuclei in a phosphorylation-dependent manner. Mol Cell Biol Res Commun 2001; 4: 374-80.
67. Xiao G-H, Shoarinejad F, Jin F, Golemis EA, Yeung RS: The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J Biol Chem 1997; 272: 6097-100.
68. Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, et al: Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell 2001; 7: 823-32.
69. Jones KA, Jiang X, Yamamoto Y, Yeung RS: Tuberin is a component of lipid rafts and mediates caveolin-1 localization: role of TSC2 in post-Golgi transport. Exp Cell Res 2004; 295: 512-24.
70. Li Y, Inoki K, Yeung R, Guan K-L: Regulation of TSC2 by 14-3-3 binding. J Biol Chem 2002; 277: 44593-6.
71. Nellist M, Goedbloed MA, DeWinter C, et al: Identification and characterization of the interaction between tuberin and 14-3-3ζ. J Biol Chem 2002; 277: 39417-29.
72. Hengstschlager M, Rosner M, Fountoulakis M, Lubec G: Tuberous sclerosis genes regulate cellular 14-3-3 protein levels. Biochem Biophys Res Commun 2003; 312: 676-83.
73. Fujita N, Sato S, Katayama K, Tsuruo T: Akt-dependent phosphorylation of p27 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002; 277: 28706-13.
74. Dery M-AC, Michaud MD, Richard DE: Hypoxia-inducible factor I: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005; 37: 535-40.
75. Brugarolas J, Vazquez F, Reddy A, Sellers WR, Kaelin WG: TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003; 4: 147-56.
76. Brugarolas J, Kaelin WG Jr.: Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 2004; 6: 7-10.
77. Brugarolas J, Lei K, Hurley RL, et al: Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004; 18: 2893-904.
78. Carsillo T, Astrinidis A, Henske EP: Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000; 97: 6085-90.
79. Bittmann I, Rolf B, Amann G, Lohrs U: Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Human Pathol 2003; 34: 95-8.
80. Karbowniczek M, Astrinidis A, Balsara BR, et al: Recurrent lymphangioleiomyomatosis after transplantation. Am J Respir Crit Care Med 2003; 167: 976-82.
81. Henske EP: Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 2003; 38: 376-81.
82. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al: Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004; 101: 17462-7.
83. Karbowniczek M, Yu J, Henske EP: Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Path 2003; 162: 491-500.
84. Hayashi T, Fleming MV, Stetler-Stevenson WG, et al: Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Human Pathol 1997; 28: 1071-8.
85. Matsui K, Takeda K, Yu Z-X, Travis WD, Moss J, Ferrans VJ: Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000; 124: 267-75.
86. Krymskaya VP, Shipley JM: Lymphangioleiomyomatosis. A complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Respir Cell Mol Biol 2003; 28: 546-50.
87. Zhe X, Yang Y, Jakkaraju S, Schuger L: Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2003; 28: 504-11.
88. Zhe X, Yang Y, Schuger L: Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor. Am J Respir Cell Mol Biol 2005; 32: 28-34.
89. Ferri N, Carragher NO, Raines EW: Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling. Am J Path 2004; 164: 1575-85.
90. Taveira-Dasilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J: Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126: 1867-74.
91. Graf-Deuel E, Knoblauch A: Simultaneous bilateral pneumothorax. Chest 1994; 105: 1142-6.
92. Berkman N, Bloom A, Cohen P, et al: Bilateral spontaneous pneumothorax as the presenting feature in lymphangioleiomyomatosis. Respir Med 1995; 89: 381-3.
93. Matsui K, Tatsuguchi A, Valencia J, et al: Extrapulmonary lymphangioleio-myomatosis (LAM): Clinicopathologic features in 22 cases. Hum Pathol 2000; 31: 1242-8.
94. Ryu JH, Doerr CH, Fisher SD, Olson EJ, Sahn SA: Chylothorax in lymphangioleiomyomatosis. Chest 2003; 123: 623-7.
95. Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J: Lymphangioleiomyomatosis: abdomino-pelvic CT and US findings. Radiology 2000; 216: 147-53.
96. Jaiswal VR, Baird J, Fleming J, Miller DS, Sharma S, Molberg K: Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature. Arch Pathol Lab Med 2003; 127: 879-82.
97. Llopis I, Arandiga R, Real E, et al: Lymphangiomyomatosis mimicking an abdominal lymphoma. Hematologica 2002; 87: EIM23.
98. Ernst JC, Sohaey R, Cary JM: Pelvic lymphangioleiomyomatosis; atypical precursor of pulmonary disease. Chest 1994; 106: 267-9.
99. Lu H-C, Wang J, Tsang Y-M, Lin M-C, Li Y-W: Lymphangioleiomyomatosis initially presenting with abdominal pain. A case report. J Clin Imag 2003; 27: 166-70.
100. Wong Y-Y, Yeung T-K, Chu WC-W: Atypical presentation of lymphangioleiomyomatosis as acute abdomen: CT diagnosis. AJR 2003; 181: 284-5.
101. Kehagias D, Pafiti A, Vaos N, Samanidis L: Retroperitoneal lymphangioleiomyomatosis: CT appearance. Eur Radiol 1998; 8: 471-3.
102. Avila NA, Bechtle J, Dwyer AJ, Ferrans VJ, Moss J: Lymphangioleiomyomatosis: CT of diurnal variation of lymphangioleiomyomas. Radiology 2001; 221: 415-21.
103. Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney International 2004; 66: 924-34.
104. Kahn SU, Mehta AC: Chyloptysis found in a patient with lymphangioleiomyomatosis. Chest 1995; 108: 1775.
105. Meysman M, Noppen M, Herregodts P, Vincken W: A patient with seizures, hemoptysis and dyspnoea. Eur Respir J 1995; 8: 1433-1434.
106. Badawi RA, Geddes DM: Exertional hemoptysis: LAM and TSC. Thorax 2003; 58: 460-3.
107. Yamamoto K, Anzai F, Kusajima K, Yamanishi N, Yamada M: Acute respiratory failure with gross hemoptysis in a patient with lymphangioleiomyomatosis as part of tuberous sclerosis complex. Intern Med 2004; 43: 755-8.
108. Moss J, DeCastro R, Patronas N, Taveira-DaSilva AM: Meningiomas in lymphangioleiomyomatosis. JAMA 2001; 286: 1879-91.
109. Jay JR, MacLaughlin DT, Riley KR, Martuza RL: Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 1985; 62: 757-62.
110. Carroll RS, Glowacka D, Dashner K, Black PM: Progesterone receptor expression in meningiomas. Cancer Res 1993; 53: 1312-16.
111. Tonn JC, Ott MM, Meixensberger J, Paulus W, Roosen K: Progesterone receptors are detectable in tumor fragment spheroids of meningiomas in vitro. Anticancer Res 1994; 14: 2453-6.
112. Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MWF, Thijssen JHH: Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 2000; 65: 795-800.
113. Grunberg SM: Role of antiprogestational therapy for meningiomas. Hum Reprod 1994; 9 (suppl 1): 202-7.
114. Valencia JC, Matsui K, Tatsuguchi A, et al: Expression of insulin-like growth factors (IGFs) in the smooth muscle cells in pulmonary lymphangioleiomyomatosis (LAM). Am J Respir Crit Care Med 2000; 161 (suppl): A15.
115. Styblo JL, Flaherty D, Li FB, Grassberg MK: Platelet-derived growth factor in LAM. Am J Respir Crit Care Med 1999; 159 (suppl): A531.
116. Maxwell M, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniades HN: Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 1990; 46: 16-21.
117. Cottin V, Vukusic S, Jouanneau E, Lazor R, Cordier J-F: Should patients with lymphangioleiomyomatosis undergo screening for meningioma? Eur Respir J 2004; 24: 888-9.
118. Taveira-Dasilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J: Bone mineral density in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2005; 171: 61-7.
119. Nishimura Y, Nakata H, Tsutsumi M, Maeda H, Yokoyama M: Relationship between changes of bone mineral content and twelve-minute walking distance in men with chronic obstructive pulmonary disease: a longitudinal study. Intern Med 1997; 36: 450-3.
120. Incalzi RA, Caradonna P, Ranieri P, et al: Correlates of osteoporosis in chronic obstructive pulmonary disease. Respir Med 2000; 94: 1079-84.
121. Brousse C, Nguyen-Plantin S, Friard S, Grenet D, Stern M: Étude de la densité minérale osseuse chez des patients insuffisants respiratoires chroniques. Rev Mal Respir 2001; 18: 411-15.
122. Tschopp O, Boehler A, Speich R, et al: Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am J Transplant 2002; 2: 167-72.
123. Biskobing DM: COPD and osteoporosis. Chest 2002; 121: 609-20.
124. Ionescu AA, Schoon E: Osteoporosis in chronic obstructive pulmonary diseases. Eur Respir J 2003; 22: 64s-75s.
125. Gluck O, Colice G: Recognizing and treating glucocorticoid-induced osteoporosis in patients with pulmonary diseases. Chest 2004; 125: 1859-76.
126. Berger JL, Shaff MI: Pulmonary lymphangioleiomyomatosis. J Comput Assist Tomogr 1981; 5: 565-7.
127. Merchant RN, Pearson MG, Rankin RN, Morgan WKC: Computerized tomography in the diagnosis of lymphangioleiomyomatosis. Am Rev Respir Dis 1985; 131: 295-7.
128. Templeton PA, McLoud TC, Muller NL, Shepard JO, Moore EH: Pulmonary lymphangioleiomyomatosis: CT and pathologic findings. J Comput Assist Tomogr 1989; 13: 54-7.
129. Rappaport DC, Weisbrod GL, Herman SJ, Chamberlain DW: Pulmonary lymphangioleiomyomatosis: high-resolution CT findings in four cases. AJR 1989; 152: 961-4.
130. Sherrier RH, Chiles C, Roggli V: Pulmonary lymphangioleiomyomatosis: CT findings. AJR 1989; 153: 937-40.
131. Müller NL, Chiles C, Kullnig P: Pulmonary lymphangiomyomatosis: correlation of CT with radiographic and functional findings. Radiology 1990; 175: 335-9.
132. Aberle DR, Hansell DM, Brown K, Tashkin DP: Lymphangiomyomatosis: CT, chest radiographic, and functional correlations. Radiology 1990, 176: 381-7.
133. Avila NA, Chen CC, Chu SC, et al: Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology 2000; 214: 441-6.
134. Avila NA, Dwyer AJ, Murphy-Johnson DV, Brooks P, Moss J: Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology 2002; 223: 189-97.
135. Crausman RS, Lynch DA, Mortensen RL, et al: Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangiomyomatosis. Chest 1996; 109: 131-7.
136. Paciocco G, Uslenghi E, Bianchi A, et al: Diffuse cystic lung diseases. Correlation between radiologic and functional status. Chest 2004; 125: 135-42.
137. Schuster TG, Ferguson MR, Baker DE, Shaldenbrand JD, Solomon MH: Papillary renal cell carcinoma containing fat without calcification mimicking angiomyolipoma on CT. AJR 2004; 183: 1402-4.
138. Avila NA, Dwyer AJ, Murphy-Johnson DV, Brooks P, Moss J: Sonography of lymphangioleiomyoma in lymphangioleiomyomatosis: demonstration of diurnal variation in lesion size. AJR 2005; 184: 459-64.
139. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al: Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2003; 168: 1427-31.
140. Sobonya RE, Quan SF, Fleishman JS: Pulmonary lymphangioleiomyomatosis: quantitative analysis of lesions producing airflow limitation. Hum Pathol 1985; 16: 1123-8.
141. Burger CD, Hyatt RE, Staats BA: Pulmonary mechanics in lymphangioleiomyomatosis. Am Rev Respir Dis 1991; 143: 1030-3.
142. Crausman RS, Jennings CA, Mortensen RL, Ackerson LM, Irvin CG, King TE: Lymphangioleiomyomatosis: the pathophysiology of diminished exercise capacity. Am J Respir Crit Care Med 1996; 153: 1368-76.
143. Koyama M, Johkoh T, Honda O, et al: Chronic cystic lung disease: Diagnostic accuracy of high-resolution CT in 92 patients. AJR 2003; 180: 827-35.
144. Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE: Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 2004; 59: 800-3.
145. Johnson S, Tattersfield AE: Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 1999; 160: 628-33.
146. 1 decline in pulmonary lymphangioleiomyomatosis. Respir Med 2004; 98: 536-41.
147. Yockey CC, Riepe RE, Ryan K: Pulmonary lymphangioleiomyomatosis complicated by pregnancy. Kansas Med 1986; 87: 277-8.
148. Brunelli A, Catalini G, Fianchini A: Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. Int J Gynaecol Obstet 1996; 52: 289-90.
149. Shen A, Iseman MD, Waldron JA, et al: Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest 1987; 91: 782-5.
150. Yano S: Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax 2002; 57: 1085-6.
151. Oberstein EM, Fleming LE, Gomez-Marin O, et al: Pulmonary lymphangioleiomyomatosis (LAM): examining oral contraceptive pills and onset of disease. J Womens Health 2003; 12: 81-5.
152. Wahedna I, Cooper S, William J, Paterson IC, Britton JR, Tattersfield AE: Relation of pulmonary lymphangioleiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study. Thorax 1994; 49: 910-14.
153. Colley MH, Geppert E, Franklin WA: Immunohistochemical detection of steroid receptors in a case of lymphangioleiomyomatosis. Am J Surg Pathol 1989; 13: 803-7.
154. Matsui K, Takeda K, Zu-Xi Y, et al: Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy: an immunochemical study. Am J Respir Crit Care Med 2000; 161: 1002-9.
155. Banner AS, Carrington CB, Emory WB, et al: Efficacy of oophorectomy in lymphangioleiomyomatosis and benign metastasizing leiomyoma. N Engl J Med 1981; 305: 204-9.
156. Logan RF, Fawcett IW: Oophorectomy for pulmonary lymphangioleiomyomatosis: A case report. Br J Dis Chest 1985; 79: 98-100.
157. Eliasson AH, Phillips YY, Tenholder MF: Treatment of lymphangioleiomyomatosis. A meta-analysis. Chest 1989; 196: 1352-55.
158. van Milligen de Wit AWM, Meilof-Planteydt MNM: Successful treatment of lymphangioleiomyomatosis with oophorectomy and medroxyprogesterone-acetate: report of a case and brief review of the literature. Netherlands J Med 1990; 36: 246-51.
159. Klein M, Krieger O, Ruckser R, et al: Treatment of lymphangioleiomyomatosis by ovariectomy, interferon alpha 2b and tamoxifen - a case report. Arch Gynecol Obstet 1992; 252: 99-102.
160. Flandes Aldeyturriaga J, Golpe Gomez A, Perez Rodriguez E: Lymphangioleiomyomatosis: The effectiveness of radiotherapy-induced ovarian function annulment. Respiration 1991; 58: 214-8.
161. Tomasian A, Greenberg MS, Rumerman H: Tamoxifen for lymphangioleiomyomatosis. N Engl J Med 1981; 306: 745-6.
162. Bettendorf U, Bauer KH, Kaiser E: Kasuistischer Beitrag zu hormonellen Aspekten in der therapie der pulmonalen Lymphangio-Leiomyomatose (LLM). Prax Klin Pneumol 1983; 37: 1024-5.
163. Svendsen TL, Viskum K, Hansborg N, et al: Pulmonary lymphangioleiomyomatosis: a case of progesterone receptor positive lymphangioleiomyomatosis treated with medroxyprogesterone, oophorectomy and tamoxifen. Br J Dis Chest 1984; 78: 264-70.
164. Sawicka, EH, Morris, JR: A report of two long-surviving cases of pulmonary lymphangioleiomyomatosis and the response to progesterone therapy. Br J Dis Chest 1985; 79: 400-6.
165. Ten Brock, E, Votto, JJ: Lymphangioleiomyomatosis: treatment with hormonal manipulation. N Y State J Med 1986; 86: 533-6.
166. Rossi GA, Balbi B, Oddera S, Lantero S, Ravazzoni C: Response to treatment with an analog of luteinizing-hormone-releasing hormone in a patient with pulmonary lymphangioleiomyomatosis. Am Rev Respir Dis 1991; 143: 174-6.
167. Tao Y, Yoshii C, Nikaido Y, et al: Two cases of lymphangioleiomyomatosis. Nihon Kyobu Shikkan Gakkai Zasshi 1993; 31: 1157-62.
168. Desurmont S, Bauters C, Copin MC, Dewailly D, Tonnel AB, Wallaert B: Traitement de la lymphangioléiomyomatose pulmonaire par un agoniste du GnRH. Rev Mal Resp 1996; 13: 300-4.
169. de la Fuente J, Parámo C, Roman F, Pérez R, Masa C, Letona JML: Lymphangioleiomyomatosis: unsuccessful treatment with luteinizing-hormone releasing hormone analogues. Eur J Med 1993; 2: 377-8.
170. Zahner J, Borchard F, Fischer H, Schneider W: Erfolgreich therapie einer postpartalen lymphangioleiomyomatose. Schweiz Med Wochenschr 1994; 124: 1626-32.
171. Medeiros Jr P, Lopes RA, Kairalla RA, Carvalho CRR: Evaluation of functional pulmonary response to gonadotrophin releasing hormone agonist (goserelin) in the treatment of lymphangioleiomyomatosis. Am J Respir Crit Care Med 2002; 165: A701.
172. Cassandro R, Bianchi A, Comel L, Longo L, Harari S: LH-RH agonist for lymphangioleiomyomatosis. Am J Respir Crit Care Med 2002; 165: A701.
173. Medeiros Jr P, Kairalla RA, Pereira CAC, et al: GnRH analogs x progesterone lung function evolution in two treatment cohort groups in lymphangioleiomyomatosis (LAM). Am J Respir Crit Care Med 2003; 167: A953.
174. Rajjoub S, Blatt MW, Ritterspach J: Response to treatment with progesterone in a patient with pulmonary lymphangioleiomyomatosis. West Virginia Med J 1995; 91: 322-3.
175. Druelle S, Aubry P, Levi-Valensi P: La lymphangiomatose pulmonaire: suivi a trois ans sous acetate de medroxyprogesterone. Rev Pneumol Clin 1995; 51: 284-7.
176. Morimoto N, Hirasaki S, Kamei T, et al: Pulmonary lymphangioleiomyomatosis (LAM) developing chylothorax. Intern Med 2000; 39: 738-41.
177. Zanella A, Toppan P, Nitti D, Lise M: Pulmonary lymphangioleiomyomatosis: A case report in postmenopausal woman treated with pleurodesis and progesterone (medroxyprogesterone acetate). Tumori 1996; 82: 96-8.
178. Boudard C, Gamondes JP, Mornex JF, Brune J: Pleuro-peritoneal Denver shunt in treatment of chronic pleurisy. Ann Cir 1998; 52: 192-6.
179. Wojcik P, Otto TJ, Jagiello R, et al: Use of pleuro-peritoneal shunt in the treatment of chronic chylothorax. Pneumonol Alergol Pol 1998; 66: 473-9.
180. Lam B, Ooi GC, Wong MP, et al: Extrapulmonary presentation of asymptomatic pulmonary lymphangioleiomyomatosis. Respirology 2003; 8: 544-7.
181. Turner Jr WW: Chylous ascites: resolution after Denver peritoneovenous shunt. South Med J 1983; 76: 539.
182. Kimura M, Morikawa T, Takeuchi K, et al: Lymphangioleiomyomatosis with chylous ascites treatment successfully by peritoneo-venous shunting. Nihon Kyobu Shikkan Gakkai Zasshi 1996; 34: 557-62.
183. Camoglio FS, Dipaola G, Cervillione RM, et al: Treatment of neonatal chylous ascites using a modified Denver peritoneovenous shunt: a case report. Pediatr Med Chir 2003; 25: 145-7.
184. Rimensberger PC, Müller-Schenker B, Kalangos A, Beghetti M: Treatment of a persistent chylothorax with somatostatin. Ann Thorac Surg 1998; 66: 253-4.
185. Widjaja A, Gratz KF, Ockenga J, Wagner S, Manns MP: Octreotide for therapy of chylous ascites in yellow nail syndrome. Gastroenterology 1999; 116: 1017-8.
186. Ferrandière M, Hazouard E, Guicheteau V, Bensenouci M, Lamotte C, Mercier C: Chylous ascites following radical nephrectomy: efficiency of octreotide as treatment of a ruptured thoracic duct. Intensive Care Med 2000; 26: 484-5.
187. Bathia C, Pratap U, Slavik Z: Octreotide therapy: a new horizon in treatment of iatrogenic chyloperitoneum. Arch Dis Child 2001; 85: 234-5.
188. Leong RWL, House AK, Jeffrey GP: Chylous ascites caused by portal vein thrombosis treated with octreotide. J Gastroenterol Hepatol 2003; 18: 1211-3.
189. Makrilakis K, Pavlatos S, Giannikopoulos G, Toubanakis C, Katsilambros N: Successful octreotide treatment of chylous pleural effusion and lymphedema in the yellow nail syndrome. Ann Intern Med 2004; 141: 246-7.
190. Hsu THS, O'Hara J, Mehta A, Levitin A, Klein EA: Nephron-sparing nephrectomy for giant renal angiomyolipoma associated with lymphangioleiomyomatosis. Urology 2002; 59: 138xxii-138xxiii.
191. Wallace BA, Cumming RG: Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women. Calcif Tissue Int 2000; 67: 10-18.
192. Kemmler W, Lauber D, Weineck J, Hensen J, Kalender W, Engelke K: Benefits of intense exercise on bone density, physical fitness, and blood lipids in early postmenopausal osteopenic women. Arch Intern Med 2004; 164: 1084-91.
193. Yeung RS: Multiple roles of the tuberous sclerosis complex genes. Genes Chromosomes Cancer 2003; 38: 368-75.
194. Kenerson H, Dundon TA, and Yeung RS: Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 2005; 57: 67-75.